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Abstract: The aggregation of alpha-synuclein (α-SYN) into fibrils is characteristic for 
several neurodegenerative diseases, including Parkinson’s disease (PD). Ninety percent of 
α-SYN deposited in Lewy Bodies, a pathological hallmark of PD, is phosphorylated on 
serine129. α-SYN can also be phosphorylated on tyrosine125, which is believed to regulate 
the membrane binding capacity and thus possibly its normal function. A better 
understanding of the effect of phosphorylation on the aggregation of α-SYN might shed 
light on its role in the pathogenesis of PD. In this study we compare the aggregation 
properties of WT α-SYN with the phospho-dead and phospho-mimic mutants S129A, 
S129D, Y125F and Y125E and in vitro phosphorylated α-SYN using turbidity, thioflavin T 
and circular dichroism measurements as well as transmission electron microscopy. We 
show that the mutants S129A and S129D behave similarly compared to wild type (WT)  
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α-SYN, while the mutants Y125F and Y125E fibrillate significantly slower, although all 
mutants form fibrillar structures similar to the WT protein. In contrast, in vitro 
phosphorylation of α-SYN on either S129 or Y125 does not significantly affect  
the fibrillization kinetics. Moreover, FK506 binding proteins (FKBPs), enzymes with  
peptidyl-prolyl cis-trans isomerase activity, still accelerate the aggregation of 
phosphorylated α-SYN in vitro, as was shown previously for WT α-SYN. In conclusion, 
our results illustrate that phosphorylation mutants can display different aggregation properties 
compared to the more biologically relevant phosphorylated form of α-SYN. 
Keywords: alpha-synuclein; phosphorylation; parkinson’s disease; phosphorylation mutants; 
FKBP; in vitro fibrillization 
 
1. Introduction 
The aggregation of alpha-synuclein (α-SYN) into fibrils is characteristic for several neurodegenerative 
diseases, including Parkinson’s disease (PD) [1]. These fibrils are deposited into Lewy bodies (LB) 
and Lewy neurites, the pathological hallmarks of PD [2]. α-SYN is a 140 amino acids long intrinsically 
disordered protein with almost no secondary structural elements and only limited tertiary intramolecular 
contacts under physiological conditions in vitro [3,4]. Although the exact function of α-SYN remains 
elusive, it might play a role in regulating dopamine neurotransmission [5,6], vesicular trafficking [7,8] 
and modulating synaptic function and plasticity [9–11]. The majority (~90%) of the α-SYN protein in 
LBs is phosphorylated at S129, compared to only about 4% in normal brain extracts [12–14]. However, 
it remains unresolved whether phosphorylation occurs before or after aggregation. It is also still 
unclear whether this modification promotes or inhibits aggregation and what effect it has on the 
neurotoxicity in vivo. It was shown that the tertiary intramolecular long-range interactions are disrupted 
in in vitro phosphorylated α-SYN, which might cause the inhibition of aggregation observed by 
Paleologou et al. [15]. Contradictory results were obtained by Fujiwara et al. where in vitro 
phosphorylated α-SYN was more prone to aggregate [13]. 
Previous studies have used the phosphorylation mutants, S129A and S129D, to mimic absence of 
phosphorylation or constitutive phosphorylation respectively, in order to investigate this effect in cells 
and in vivo. While the phosphorylation mimicking mutant (S129D) promoted cell death in a 
Drosophila model [16] as well as in neuroblastoma cell lines [11,17], this was not the case in viral 
vector-mediated rat models. Whereas two studies report accelerated dopaminergic neuronal loss with 
the S129A mutant and a moderate to significant protective effect of the S129D mutant compared to  
wild-type α-SYN [18,19], McFarland and colleagues found no significant differences between both 
phosphorylation mutants and wild-type α-SYN in nigrostriatal toxicity or aggregation [20]. 
Several kinases have been shown to phosphorylate α-SYN in vitro on S129, such as casein kinase I 
(CKI), CKII [13,21,22], G-protein coupled receptor kinases (GRK) [23,24] and members of the  
polo-like kinase family (PLK2) [25,26]. CKI and CKII phosphorylate on S87 as well, albeit to a lesser 
extent [15,21]. Two recent studies showed that PLK2, also known as serum-inducible kinase (SNK),  
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is a major contributor of pS129-α-SYN in primary neuronal cultures and in transgenic mice [25,26]. 
Moreover, PLK2 levels are elevated in brains of Alzheimer disease and dementia with LB patients [26]. 
In vitro phosphorylation on tyrosines of α-SYN has been described for several kinases such as  
Syk kinase [27], SRC kinases [28] and Fyn kinase, the latter specifically phosphorylating Y125 of  
α-SYN [29]. The phosphorylation on Y125 is thought to regulate α-SYN membrane binding and the 
inhibition of phospholipase D2 by α-SYN [30]. Phosphorylation on all three tyrosines in the  
C-terminal part by SYK kinase was reported to prevent aggregation in vitro [27]. Recently it was 
shown that tyrosine phosphorylation of α-SYN might protect against neurotoxicity in a Drosophila 
model of PD [31]. Overexpression of the Drosophila homologue of SYK kinase even rescued the 
toxicity of the phospho-mimicking mutant S129D. 
In this study we performed a systematic comparison of the biochemical properties of normal α-SYN 
WT with α-SYN phosphorylation mutants (S129A/D and Y125F/E) and in vitro phosphorylated  
α-SYN. Our group previously showed that the enzyme FKBP12 (FK506 binding protein 12)  
(EC. 5.2.1.8.), which is a cis-trans proline isomerase from the family of FK506 binding proteins, 
accelerates the aggregation of WT α-SYN [32–34]. Since α-SYN’s five proline residues, as well as the 
major phosphorylation sites, are all located in the C-terminus, we investigated the influence of α-SYN 
phosphorylation at either S129 or Y125 on this acceleration. 
Our results show that phosphorylation mutants of α-SYN do not fully reproduce the behaviour of  
α-SYN phosphorylated with physiologically relevant kinases. They also suggest that phosphorylation 
does not necessarily promote aggregation. Furthermore, the ability of FKBP12 to accelerate α-SYN 
aggregation is comparable between phosphorylated and WT α-SYN. 
2. Results and Discussion 
2.1. Construction and Production of the α-SYN Phosphorylation Mutants S129A/D and Y125F/E 
We wanted to generate phosphorylation mimicking mutants S129D and Y125E as well as their 
respective negative control mutants, S129A and Y125F in order to characterize their in vitro aggregation 
properties. By replacing Ser or Tyr with an acidic amino acid (Asp or Glu) one can mimic the electrostatic 
features of a phosphorylated residue, although it should be noted that the phosphate group on Ser or 
Tyr is fully deprotonated at pH 7.4 which results in a net charge of −2 instead of −1 with Asp/Glu. The 
structural similarities between Ser and Asp make this replacement a reasonable phospho-mimicking 
mutation, although it should be noted that the distance between the alpha carbon and the negative 
charge is longer in the phosphoserine compared to Asp. The structures of Tyr and Glu are much less 
alike, but since no aromatic acidic amino acid is available the choices are limited. Using far UV-CD 
measurements we could confirm that the spectra of all mutants were comparable to that of the WT 
protein and represented a predominantly random coil structure (Figure 1A), corresponding well with 
the values of monomeric WT α-SYN reported in literature [35]. 
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Figure 1. Far UV-CD spectra of WT α-SYN and its phosphorylation mutants and fibrillization 
of WT α-SYN compared to the phosphorylation mutants. (A) Far UV-CD spectra of α-SYN 
and phosphorylation mutants were taken at the start point of further measurements to 
account for possible secondary structure differences due to the mutations. All spectra have 
a minimum near 200 nm, typical for a random coil structure. The phosphorylation mutants 
(Y125F (cyan), Y125E (dark cyan), S129A (pink), S129D (purple)) show spectra similar to 
that of the WT protein (black), and our obtained values of approximately −20,000 MRE 
(mean residue ellipticity) correspond well to values of monomeric WT α-SYN found in 
literature. The kinetics of the fibrillization process of α-SYN WT and phospho-mutants 
were followed by a Thioflavin T assay under continuous shaking (270 rpm) at 37 °C.  
A concentration of 50 µM α-SYN was used in each experiment; (B) Mean values of the 
halftimes; The halftimes of fibrillization are expressed as percentages of WT, which was 
set to 100%; (C) Representative figure showing an inhibitory effect with both tyrosine 
mutants (Y125F (white squares) and Y125E (gray squares)). The kinetics of both serine 
mutants, however, are similar to that of the WT protein (S129A (white triangles), S129D 
(gray triangles) and WT (white circles)); (D) Mean end phase fluorescence intensities;  
(B) and (D) are calculated from 5 independent measurements (n = 5) each done  
in quadruplicate, with the standard error of mean (SEM) shown on each bar.  
* and *** indicate a statistical significant difference when compared to WT with a  
p-value < 0.05 and < 0.001 respectively; TEM images were taken and are represented in (E), 
from left to right: S129A, S129D, WT, Y125E, Y125F. The scale bars are set to 200 nm. 
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Figure 1. Cont. 
 
2.2. In Vitro Aggregation Properties of the Phosphorylation Mutants 
First, we assessed fibril formation by a thioflavin T (ThioT) assay (Figure 1B–D). The curves were 
fitted with a sigmoid model to obtain the half-time of aggregation (t1/2(aggregation)) as well as the end 
phase amplitude, which correlates to the amount of fibrils formed (Figure 1B,D). The fibrillization of 
both tyrosine mutants Y125E and Y125F was significantly slower with a half time approximately 
twice as long as for WT α-SYN (Figure 1B). Moreover, the plateau was reached at lower fluorescence 
intensities (Figure 1D). None of the serine mutants showed a significant difference when compared to 
WT α-SYN, although the S129A mutant tended to aggregate faster than the wild-type protein  
(Figure 1B,C). When the stationary phase was reached, electron microscopy analysis was used to 
examine the morphology of the aggregates formed (Figure 1E). Fibrils were present in all samples and 
their morphology was similar to that of WT α-SYN, confirming that differences in aggregation kinetics 
between α-SYN variants are due to true kinetic differences, rather than to hypothetical differences in 
aggregation pathways. Turbidity experiments were also performed to investigate the general 
aggregation properties (Supplementary Figure S1). Overall, the turbidity measurements of the 
phosphorylation mutants followed the same trends as the ThioT measurements. Due to a higher variation 
between independent measurements, the only significant difference in t1/2(aggregation) was obtained 
between WT and the Y125F mutant (Supplementary Figure S1B), while the Y125E phosphorylation 
mimic mutant reached a significantly lower end phase amplitude (Supplementary Figure S1C). 
2.3. In Vitro Phosphorylation of α-SYN on Different Residues 
The reported specificity of Casein Kinase II (CKII) for phosphorylating α-SYN on S129 and to a 
lesser extent S87 [13,21,22] was first confirmed by in vitro phosphorylation of WT and S129A α-SYN 
using a radioactive assay. The phosphate incorporation was measured by autoradiography. Phosphorylation 
was indeed mainly on S129, since only after longer incubation times a band became visible with the 
S129A mutant (Figure 2A,B). PLK2 however, was even more specific in phosphorylating α-SYN on 
S129, including after 24 h incubation (Figure 2C,D) as reported before [26]. Using a scintillation 
counting based quantification of phosphate incorporation, we determined that PLK2 phosphorylates  
α-SYN very efficiently (0.72 phosphates per α-SYN molecule) unlike CKII phosphorylation where  
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the yield was only about 2%. Therefore, we used PLK2 to phosphorylate α-SYN on S129 for all 
further experiments. 
In view of reported differential effects of phosphorylation on Y125 compared to phosphorylation on 
S129 on cell death and α-SYN aggregation in a Drosophila model [31], we determined the influence  
of Y125 phosphorylation on the aggregation of α-SYN in vitro. We tested two kinases: SRC and  
Fyn kinase. SRC kinase did not phosphorylate specifically on Y125, as was shown by autoradiography 
(Figure 2E,F). Phosphorylation with Fyn kinase showed higher specificity for Y125 at early time 
points, although background signal in the Y125E control could be observed at longer incubation  
times indicating that a small proportion of other tyrosine sites are phosphorylated (Figure 2G,H). By 
calculation of the molar ratios of incorporated phosphates per α-SYN molecule, we determined that 
1.49 phosphates per α-SYN molecule are incorporated for SRC phosphorylation and 1.18 for  
Fyn phosphorylation. Taking into account that the incorporation of a radioactive phosphoryl group in 
the Y125E mutants was 0.69 and 0.42 respectively, both kinases show a similar efficiency of Y125 
phosphorylation (0.79 and 0.76 respectively). Since phosphorylation with Fyn kinase was more 
specific we decided to further use only this kinase. 
2.4. Structural Properties of in Vitro Phosphorylated α-SYN 
CD measurements were performed after the α-SYN phosphorylation (overnight phosphorylation,  
as described in materials and methods) to see if the incorporation of a phosphoryl group affects  
the native structure of the protein. All spectra correlated to an unfolded structure similar to the  
WT protein (Figure 2I). 
For the control, unphosphorylated WT α-SYN, all manipulations of the phosphorylation protocol 
with the exception of ATP/kinase addition were carried out for all further experiments, to rule out any 
influence this assay might have on the aggregation properties of the protein. This control (indicated as 
“WT ctrl”) is also represented by an unfolded CD spectrum (Figure 2I). 
Early oligomerisation events of α-SYN can be followed by FCS by the addition of trace amounts 
of A140C-α-SYN labeled with Alexa 488 [36]. With this technique a distribution of diffusion 
coefficients (D) is obtained, which correlates to the size of the diffusing particles. At the starting point 
of each experiment we observed a homogeneous distribution and the obtained D corresponds to the 
monomeric form of the protein [36]. This was also the case for α-SYN phosphorylated on S129 
(pS129-α-SYN) as well as on Y125 (pY125-α-SYN) (Supplementary Figure S2). The mean diffusion 
coefficient of 4 independent measurements was calculated, which was similar for pS129-α-SYN  
(92.0 +/− 6.57 µm2/s), pY125-α-SYN (92.3 +/− 3.84 µm2/s) and their control (unphosphorylated WT 
α-SYN (WT ctl: 86.4 +/− 4.95 µm2/s)) (Supplementary Figure S2A). From the diffusion coefficients 
the hydrodynamic radius can be calculated, assuming a spherical particle, which ranged from  
23.9 (+/− 1.4) Å for pY125-α-SYN, 24.3 (+/− 1.7) Å for pS129-α-SYN to 25.8 (+/− 2.9) Å for WT ctl 
(Supplementary Figure S2B). These values were not significantly different and correspond to the 
previously reported hydrodynamic radius for monomeric WT α-SYN of 26.6 Å [37] or 28.2 Å [15,38]. 
It should be noted that alternative techniques, such as NMR based techniques have yielded higher 
hydrodynamic radii for phosphorylated α-SYN (35.3 Å for S129 phosphorylated α-SYN) [15], perhaps 
because these techniques do not require assumptions on particle shape. 
Int. J. Mol. Sci. 2014, 15 1046 
 
Figure 2. Phosphate incorporation using autoradiography and far UV-CD spectra of 
(phosphorylated)-α-SYN. Phosphate incorporation was monitored by a radioactivity assay, 
where ATP-P32 was incubated in the presence of different kinases and WT α-SYN or the 
S129A/ Y125E mutant. The reaction was stopped at different time points (15 min, 30 min, 
1 h, 2 h, 3 h as well as 24 h for PLK2 and Fyn) with SDS-loading dye and boiling for  
5 min. Radioactive phosphate incorporation was visualised by autoradiography, after which 
western blotting was performed to detect relative protein levels. For each time point WT 
and a respective mutant were used. WT: WT α-SYN, A: S129A α-SYN, E: Y125E α-SYN, 
-ctl: negative control (kinase boiled for five min prior to test). Cas: casein kinase, used as a 
positive control for serine phosphorylation. Kinases and the kinase concentrations used in 
the in vitro phosphorylation assays are given between the blot panels (please refer to the 
Materials and Methods section for full details on the kinases and phosphorylation procedure) 
(A) radio-activity blot of CKII phosphorylation; (B) western blot of (A); (C) radioactivity 
blot of PLK2 phosphorylation; (D) western blot of (C); (E) radioactivity blot of SRC 
phosphorylation; (F) western blot of (E); (G) radioactivity blot of Fyn phosphorylation; 
(H) western blot of (G); (I) Far UV-CD spectra of proteins after overnight phosphorylation. 
All spectra show a minimum near 200 nm comparable to that of WT α-SYN (black line), 
typical for a random coil structure. The manipulations necessary for phosphorylation and 
removal of ATP afterwards do not disturb the secondary structure (compare spectrum of 
WT control (black line) to that of the WT protein (gray line)). pY125-α-SYN: WT α-SYN 
phosphorylated by Fyn kinase (blue line) and pS129-α-SYN: WT α-SYN phosphorylated 
by PLK2 kinase (yellow line); and (J) Far UV–CD spectra of pS129-α-SYN (yellow line), 
pY125-α-SYN (cyan) and their control (WT ctl (black line)), prepared as in (I), after 8 h of 
continuous agitation. All samples show predominantly a β-sheet structure. 
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2.5. The Influence of pS129- and pY125-α-SYN on Its in Vitro Fibril Formation 
Next, we used the ThioT assay to assess fibril formation upon in vitro phosphorylation of α-SYN on 
either pS129 or Y125. A slightly longer t1/2(aggregation) was observed compared to the unphosphorylated 
control (WT ctl), although this difference was not significant (Figure 3A,B). Moreover, no significant 
difference was observed in end phase amplitude (Figure 3A,C). These ThioT measurements show that 
in vitro phosphorylation of α-SYN does not significantly influence the fibrillization kinetics of  
α-SYN under the conditions tested. TEM images taken after the ThioT assay showed that both  
pS129- and pY125-α-SYN formed fibrils comparable to WT Ctl (Figure 3D), confirming that the 
phosphorylation also did not induce alternate forms of aggregation. 
Please note that since we observed that the presence of ATP influences the aggregation of α-SYN 
(Supplementary Figure S3), ATP was removed by buffer exchange before the aggregation properties 
were determined. 
Int. J. Mol. Sci. 2014, 15 1048 
 
Part of the samples used for the ThioT measurements was subjected to mass spectrometry to verify 
the phosphorylation state of the protein. With PLK2 only S129 was phosphorylated, and the extent of 
phosphorylation was determined to be 46% by MALDI-TOF/TOF analysis and 35% by LC-ESI-MS/MS 
analysis (See Supplementary Figure S4A). FYN kinase phosphorylated Y125, although Y133 or  
Y136 were also phosphorylated.The percentage of tyrosine phosphorylated alpha-synuclein was  
determined by MALDI-TOF/TOF analysis to be 71% and by LC-ESI-MS/MS analysis to be 52%  
(See Supplementary Figure S4B). 
Figure 3. Fibrillization of (phosphorylated)-α-SYN. The kinetics of fibrillization of 
phosphorylated α-SYN (30 µM) monitored by ThioT fluorescence. Before the ThioT assay 
all samples were incubated overnight at 30 °C with ATP and the respective kinases. The 
next day ATP was removed by buffer exchange as described in Materials and Methods. 
The control was subjected to the same incubations/buffer exchange without the addition  
of ATP/kinase. (A) Representative measurement showing comparable kinetics of  
pY125-α-SYN (black squares), pS129-α-SYN (gray triangles) and WT ctl (white circles); 
(B) Mean halftimes and (C) mean end phase amplitudes, obtained from five independent 
measurements (n = 5) each done in quadruplicate, SEM is shown on each bar. The values 
of pS129-α-SYN and pY125-α-SYN are expressed as percent of their control (WT Ctl);  
and (D) TEM images were taken at the end of the measurements to confirm fibril 
formation. From left to right: WT ctl, pS129: pS129-α-SYN, pY125: pY125-α-SYN.  
Scale bars are set to 200 nm. 
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Next, CD measurements were carried out to follow the formation of β-sheet structure. pS129-α-SYN 
first started to form β-sheets after five h under continuous agitation. After eight h all samples showed  
mostly a β-sheet structure (Figure 2J). This correlates with the fibrillization kinetics seen in the  
ThioT measurements. 
2.6. Does FKBP12 Still Accelerate the Fibrillization of Phosphorylated α-SYN? 
It was previously shown in our lab that the enzyme FKBP12, which is a peptidyl–prolyl isomerase, 
accelerates the fibrillization of α-SYN [32–34,39]. Because in α-SYN all the proline residues are 
situated in the C-terminus (P108, P117, P120, P128, P138) [40], where also the phosphorylation events 
take place, we wondered whether phosphorylating the C-terminal part would affect this acceleration.  
It appears from the ThioT measurements that FKBP12 can still accelerate the fibrillization process of 
α-SYN phosphorylated on either residue (S129 or Y125). In our assay the acceleration of WT α-SYN 
due to FKBP12 was significant from a concentration of 1 µM FKBP12 onwards, as can be seen by a 
reduction in halftime of about 50% at 1 µM FKBP12 which increased to 74% at 10 µM FKBP12 
(Figure 4A). No clear effect of FKBP12 on the mean end phase amplitude was observed (data not shown).  
In the case of pS129-α-SYN the enhanced acceleration in the presence of FKBP12, was similar to 
that of WT α-SYN, with a reduction in halftime of 44% at 1 µM FKBP12 which increased to 69% in 
the 10 µM FKBP12 condition. Here, a tendency towards reduced halftimes was also seen at lower 
concentrations of FKBP12 (100 pM) (Figure 4B). Due to a high variation between different measurements 
no significant differences were observed in the mean end phase amplitudes. 
The acceleration due to FKBP12 on pY125-α-SYN was comparable to the acceleration on WT  
α-SYN, although at the concentration of 100 pM FKBP12 a significantly reduced halftime of about 
34% was reached, which increased to 44% in the condition with 1 µM FKBP12 (Figure 4C). As was 
the case for WT and pS129 α-SYN, here again, no clear effect of FKBP12 on the end phase amplitude 
was observed (data not shown). 
2.7. Discussion 
The fact that 90% of the fibrillar α-SYN in LBs is phosphorylated on S129 [12–14] raises questions 
on the role of this phosphorylation event in PD. Since 2005, when the results from Chen and Feany 
showed a clear correlation between phosphorylation and toxicity in a Drosophila model of PD, increasing 
research efforts have focused on the phosphorylation events of α-SYN and disease propagation [16]. 
Phospho-mimicking mutants and the corresponding non-phosphorylatable mutants are now widely 
used as respectively positive and negative controls for phosphorylated α-SYN both in vivo and in cell 
culture models [16–19,31,41,42]. In the present work, we performed an extensive in vitro study of the 
following phosphorylation mutants for the two most important phosphorylation sites in α-SYN: 
S129D/A and Y125E/F and compared their behaviour with in vitro phosphorylated α-SYN. 
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Figure 4. The influence of FKBP12 on the fibrillization of (phosphorylated)-α-SYN. The 
influence of FKBP12 on the fibrillization kinetics of WT α-SYN (A); pS129-α-SYN (B) 
and pY125-α-SYN (C) (all 30 µM). For FKBP12 a concentration range was used: no 
FKBP12, 1 pM FKBP12, 100 pM FKBP12, 10 nM FKBP12, 1 µM FKBP12 and 10 µM 
FKBP12. Mean halftimes are shown and were obtained from four independent measurements 
(n = 4) each done in quadruplicate, SEM is shown on the bars. The conditions  
with FKBP12 present are expressed as percentages of the respective control: α-SYN  
(WT, pS129 or pY125) without FKBP12, *, ** and *** indicate a statistical  
significant difference when compared to WT with a p-value < 0.05, a p-value < 0.01 or a  
p-value < 0.001 respectively; and (D) Values of aggregation half-times from Figure 4 are 
plotted in an x–y plot and a dose response curve is fitted using GraphPad Prism  
(least squares method, fit equation is Y = Bottom + (Top − Bottom)/(1 + 10(X – log EC50)).  
The EC50 values of FKBP12 in reducing the aggregation half-time of the different α-SYN 
variants are comparable for all experimental groups, ranging from 0.6 to 1 µM. WT, normal 
α-SYN; pS129, α-SYN phosphorylated at S129 by PLK2; pY125, α-SYN phosphorylated 
at Y125 by Fyn kinase.  
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2.7.1. The Y125 Phosphorylation Mutants Display Different Aggregation Properties Compared to  
in Vitro Phosphorylated α-SYN 
We demonstrate here that the S129D and the S129A mutation do not significantly influence the 
aggregation properties of α-SYN (although there is a tendency towards faster aggregation for the 
S129A variant). In contrast, both the Y125E and the Y125F mutations induced a twofold deceleration 
in the aggregation kinetics compared to wild type. These findings show that phosphorylation mutants 
at Y125 influence the aggregation process of α-SYN; however the lack of effect in the Y125 
phosphorylated form of α-SYN argues against the use of Y125E and Y125F as positive and negative 
controls in phosphorylation studies since especially the negative control (Y125F) follows different 
aggregation kinetics than WT α-SYN. These position-related effects raise the question whether the 
phospho-mimicking mutants reproduce the properties of phosphorylated α-SYN. Paleologou and 
colleagues performed a similar study on the phosphorylation mutants of S129. They saw a significantly 
accelerated fibrillization of the S129A mutant compared to WT, while the phospho-mimicking mutant 
S129D slowed down this process [15]. We observed a similar trend in our assay; however differences 
did not reach statistical significance. The effects observed for phospho-dead mutants (S129A and 
Y125F) on aggregation kinetics of α-SYN suggest that structural effects as opposed to charge effects 
on the α-SYN protein at these positions are contributing to changes in aggregation properties of α-SYN. 
Our data stress the importance of single amino acid changes in the aggregation kinetics of α-SYN. 
This conclusion is in accordance with previous studies reporting that monomeric α-SYN is stabilized 
by long-range intramolecular interactions between the C-terminal portion (res 120–140) and the central 
NAC domain [3,4,43]. This study proposed that if these interactions are mainly hydrophobic, then the 
three tyrosines (Tyr) in the C-terminal part would be important (Y125, Y133, Y136). Indeed, mutation 
of these three tyrosine residues to alanines completely inhibited the fibrillization of α-SYN. For the 
single Y125F mutant only a mild inhibitory effect was observed, which is in agreement with our 
results. However, contradictory results have also been observed since disruption of the long-range 
interactions by increasing the temperature caused accelerated aggregation [3]. The explanation might 
be that in some cases residual interactions are present, which can form off-pathway oligomers, or 
decrease intermolecular interactions that lead to fibrils by adopting an auto-inhibitory conformation. In 
favour of the off-pathway oligomer mechanism of action, it has been shown that Tyr nitration 
stabilizes specific oligomers, which also inhibits fibrillization [44,45]. 
2.7.2. In Vitro Phosphorylation of α-SYN on S129 or Y125 Does not Affect the Fibrillization Process 
Extensive in vitro studies have focused on the effect of pS129 on the aggregation properties of α-SYN 
in order to solve the question at what point this phosphorylation event takes place in LB pathogenesis. 
As was stated above, promotion as well as inhibition of fibril formation [13,15,22,38] has been observed. 
Our data show that pS129-α-SYN displays comparable fibrillization kinetics to the WT protein  
in vitro. Of course, it is interesting to look into the differences in experimental setup between these 
studies to identify important factors that determine the aggregation kinetics. A first discrepancy between 
the reported data is the phosphorylation degree of the α-SYN protein used in the fibrillization assays. 
A second difference is the identity and specificity of the kinase used e.g., CKI (partial phosphorylation, 
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rather aspecific), CKII (partial phosphorylation, rather specific) and PLK2 (strong phosphorylation, 
specific [26] and our results). For instance, inhibition of α-SYN aggregation has been reported for CKI 
phosphorylated α-SYN [15], however, this study uses an S87A α-SYN variant (rather than WT) to 
avoid CKI phosphorylation of S87. Another study examining the role of the S87 site shows that this 
site can regulate α-SYN fibrillization [38], suggesting that effects of phosphorylation of S129 are 
different for WT compared to S87A α-SYN, and providing a reconciling explanation for the apparent 
discrepancy with the present study. Since we only obtained a phosphorylation degree of 44% with 
PLK2, we cannot rule out the possibility that fully phosphorylated α-SYN aggregates differently. 
However, in a cellular environment a pool of 100% phosphorylated α-SYN is unlikely. From our data 
it can be concluded that phosphorylation of α-SYN is not necessary and does not appear to promote the 
aggregation. This suggests also that phosphorylation of α-SYN affects its interaction with cellular 
components such as other proteins or metals, as previously has been reported [46]. 
We could not observe an effect of α-SYN phosphorylation at Y125 on fibrillization kinetics, in 
contrast with the phospho-mimic mutant Y125E. This strongly suggests that the latter cannot be considered 
as a positive control for phosphorylation. The phosphorylation degree at Y125 of these samples used in 
ThioT experiments was determined to be 71%, although Y133 or Y136 were also partially phosphorylated. 
We cannot fully exclude that our observations may be secondary to effects of phosphorylation at these 
sites, however the Y125 remains the primary phosphorylated tyrosine in our tests. Our observations are 
in contrast with previously reported results, where phosphorylation by SYK kinase on all three tyrosines 
in the C-terminus inhibited eosin-induced oligomerisation [27]. This discrepancy might be due to 
different assays used. Negro et al. [27] used a very short incubation period and focused on early oligomer 
formation while we looked at fibril formation. Moreover, the construct used was a His-tagged form of  
α-SYN. We have recently shown that the His-tag affects the aggregation behaviour of α-SYN [40].  
In contrast, a more recent study using a semi-synthetic α-SYN protein phosphorylated at Y125 shows 
that aggregation of pY125 α-SYN is comparable to WT α-SYN after 24 and 48 h of aggregation [47]. 
Crucially, we show in detailed aggregation kinetics experiments that both WT and pY125 α-SYN 
aggregate at comparable speeds and that half-times of aggregation are less than 24 h, showing that 
measures at short time points (24 h or less) are required to observe differences using a ThioT readout.  
Research on Y125 phosphorylation has been primarily focused on the identification of possible 
kinases and implications for the normal function of α-SYN. pY125-α-SYN has only recently  
been linked with the pathogenesis of PD. Chen and Feany showed that increased phosphorylation  
on Y125 decreased neurotoxicity in a Drosophila model of PD [16]. Interestingly this correlated with 
less oligomer formation. pY125-α-SYN could even rescue the toxicity caused by overexpression of the 
‘phospho-mimicking’ S129D mutant [31]. Moreover, a triple tyrosine mutant Y(125,133,136)A caused 
accelerated neurotoxicity and enhanced oligomer formation, whereas it completely inhibited fibrillization 
in vitro, possibly by formation of stable off-pathway oligomers as mentioned before [48].  
In humans as well as in transgenic Drosophila, phosphorylation on Y125 decreases with age.  
In patients with Dementia with Lewy Bodies no Y125 phosphorylation could be detected in contrast to 
the controls [31]. This might mean that one of the first necessary steps in the pathogenesis of PD is 
loss of this protective pY125-α-SYN. Our own data show that pY125-α-SYN still has the capacity to 
form fibrils at rates comparable to WT, but in a cellular environment this might be prevented through 
interactions with other proteins. 
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2.7.3. FKBP12 Mediated Acceleration of Fibrillization Is Unaltered for Phosphorylated α-SYN 
FKBP12 is a FK506 binding protein belonging to the family of immunophilins. These enzymes all 
have cis-trans peptidyl prolyl isomerase (PPIAse) activity [49]. It has been shown that FK506, an 
immunosuppressive drug, and related non-immunosuppressive analogs, exhibit neuroregenerative and 
neuroprotective properties [50–52]. Our group demonstrated an accelerating effect of FKBP12 on the 
aggregation of α-SYN in vitro [33,39], an effect that is attributed to FKBP12’s PPIase activity as an 
enzymatically inactive FKBP12 does not influence α-SYN fibril formation [33]. More recently 
involvement of FKBPs in a cell culture model of synucleinopathy was reported [34]. Moreover,  
in mouse brain FK506 also reduced α-SYN aggregation and neurodegeneration [34]. In this study we 
addressed the question whether phosphorylation on S129 and/or Y125 could affect the accelerating 
ability of FKBP12 on the aggregation of α-SYN in vitro. Indeed, both residues are in close proximity 
of proline residues (P108, P117, P120, P128, and P138) which are the likely targets of FKBP12  
action [40]. Our data show that FKBP12 can enhance the fibrillization of phosphorylated α-SYN 
comparable to the observed acceleration seen with WT α-SYN. However, we cannot exclude that 
phosphorylation might still play a regulatory role in a cellular environment. 
3. Experimental Section  
3.1. Purification of α-Synuclein (α-SYN) 
Wild type (WT) α-SYN (140 aa) and its mutants were expressed and purified as described before [53]. 
3.2. Construction of Phosphorylation Mutants of α-Synuclein (α-SYN) 
The following mutations were made using site-directed mutagenesis (QuikChange XL, Stratagene, 
La Jolla, CA, USA): S129A-α-SYN, S129D-α-SYN, Y125F-α-SYN and Y125E-α-SYN, according to 
the manufacturer’s protocol. For fluorescent labeling of α-SYN, the A140C mutant gene was kindly 
provided by Prof. V. Subramaniam (Biophysical Engineering Group, Unversity of Twente, Enschede, 
The Netherlands). The purification protocol used for the phosphorylation mutants was identical to that 
of WT protein. 
3.3. SDS PAGE 
Ten microgram of WT α-SYN or its mutants was loaded on a 16% polyacrylamide Sodium Dodecyl 
Sulphate gel after addition of SDS loading dye, boiling for five min and a short centrifugation step of 
each sample. Gels were run at 35 mA for 1 h in an electrophoresis tray. 
3.4. Fluorescence Correlation Spectroscopy (FCS) 
In fluorescence correlation spectroscopy (FCS), the diffusion coefficient of a fluorescent molecule 
is calculated from the autocorrelation function of the fluctuating fluorescence signal, resulting from the 
diffusion of fluorescent molecules through the confocal volume. 
Measurements were performed on the LSM 510/ConfoCor II combination (Zeiss, Jena, Germany). 
Experiments were done with 5–6 nM labeled protein [A140C-Alexa 488-α-SYN, (Alexa 488–C5-maleimide 
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(Molecular Probes, Life Technologies, Carlsbad, CA, USA))] mixed with different concentrations of 
unlabeled protein (30–100 µM), to ensure that the number of fluorescent molecules in the confocal 
volume (0.312 fL) is limited to 1–10. For mathematical background and labeling procedure see 
Supporting Information. 
3.5. Circular Dichroism 
α-SYN WT and mutants were centrifuged for 30 min at 8500 g (Galaxy 14D centrifuge, Sorvall, 
VWR, Geel, Belgium) prior to the experiments to remove pre-existing aggregates. Samples were 
incubated at 37 °C while stirring (~200 rpm). Far-UV CD spectra were recorded on a Jasco-810 
spectrophotometer (Jasco, IJselstein, The Netherlands) in a 1 mm path length Quartz cuvette at room 
temperature. Spectra were recorded from 195 to 260 nm with a step size of 1 nm and a scanning speed 
of 20 nm/min. An average of 3 scans was recorded. All spectra were corrected by subtracting the 
background spectrum of the buffer. For every time point, aliquots were taken from the samples and diluted 
to 0.2 mg/mL in 20 mM Tris-HCl, pH 7.4, at 20 °C. 
3.6. Turbidity and Thioflavin T Measurements 
Prior to each experiment, the pre-existing aggregates were removed by centrifugation as described 
above. The samples were further diluted in 20 mM Tris-HCl pH 7.4 to the indicated concentrations and 
NaCl was added up to 100 mM, unless otherwise stated. For thioflavin T experiments 50 µM of ThioT 
(Sigma-Aldrich, St. Louis, MO, USA) was added. 
All samples were incubated in a flat-bottom transparent 96-well plate (Greiner, Bio-One, Hemmel, 
Belgium) at 37 °C with continuous shaking (~270 rpm) in a Safire2 plate reader (TECAN, Mechelen, 
Belgium). Every 1000 s, the turbidity of the samples was determined by measuring the absorbance at 
350 nm, ThioT fluorescence was measured at 482 nm (excitation at 446 nm). To reduce the number of 
data points and simplify the graphics, every fifth time point was visualized. The samples were made in 
triplicate and each experiment was repeated at least three times independently. Every graph is a 
representative example. 
3.7. Data Fitting and Statistical Analysis of ThioT and Turbidity Data 
All aggregation curves were fitted with SIGMAPLOT version 8 (Systat Software Inc., San Jose, 
CA, USA) to a three-parameter sigmoidal model to extract the relevant aggregation parameters  
(see Equation (1)). 
 bxxe
ay
01   (1)
in which y is the turbidity or ThioT fluorescence signal, x is the time, a is the total increase in 
absorbance or fluorescence, x0 is the half-time of aggregation and 1/b describes the slope of the curve 
at its mid-point and is also the rate constant of aggregation at this point. For statistical analysis all 
groups were first compared to identify significant differences through an ANOVA one-way analysis of 
variance, followed by a Tukey’s post test to compare all pairs of columns. 
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3.8. Phosphorylation Assay 
Two microgram of α-SYN was incubated with the respective kinases, 6 µCi of ATP-γ-phosphate 
(PerkinElmer, Norwalk, CT, USA) and 10 µM of cold ATP in buffer A (20 mM Tris pH 7.4, 10 mM 
MgCl2, 5 mM β-glycerophosphate, 0.1 mM Na3VO4, 2 mM DTT) in a total volume of 10 µL for the 
indicated time points. The reaction was stopped by adding 1% SDS solution and boiling for 5 min. 
The following concentrations of the kinases were used: 7.9 nM/reaction of Casein Kinase II (CKII) 
(Specific activity = 2540 pmol/µg·min) (Biaffin, Kassel, Germany); 320 nM/reaction of Polo-like 
kinase 2 (PLK2) (Specific activity = 69 pmol/µg·min) (Proqinase, Freiburg, Germany); 164 nM/reaction of 
Sarcoma (SRC) kinase (Specific activity = 142 pmol/µg·min) (Biaffin); 103 nM/reaction of FYN 
kinase (Specific activity = 87 pmol/µg·min) (Proqinase). 
Samples were resolved on a NuPAGE 10% bis-Tris pre-casted gel (Invitrogen, Merelbeke, 
Belgium) in 1× MES buffer. The samples were transferred to a nitrocellulose membrane by semi-dry 
blotting according to the manufacturer’s protocol. Phosphate incorporation was measured by 
autoradiography where the membrane was exposed to a phosphorescence plate (GE healthcare, 
Sunnyvale, CA, USA). The densitometric quantification of the autoradiogram was done using AIDA 
image analyzer (Software Verise, Straubenhardt, Germany). Equal loading was confirmed by western 
blotting using an anti-α-SYN antibody (see below). 
The degree of phosphorylation of alpha-synuclein was also tested for these samples in a separate 
experiment, in which the radioactively phosphorylated α-SYN was separated via SDS-PAGE  
(as described above) and the gel stained using Coomassie Brilliant Blue according to the manufacturer’s 
instructions (Thermo Scientific, Pittsburgh, PA, USA). Gel bands were excised and submitted to 
scintillation counting and calculation of incorporated phosphates, as previously described [54]. 
In order to prepare in vitro phosphorylated α-SYN for further experiments (including far UV-CD 
measurements, mass spectrometry analysis as well as fibrillization experiments), the following 
protocol was used: 1 mg of recombinant α-SYN was phosphorylated with CKII, PLK2, SRC or  
Fyn kinase in 600 µL buffer A. Each reaction was incubated overnight at 30 °C in the presence of  
1 mM ATP. The concentration of kinase used was 61.7 µM for CKII, 17.22 µM for Fyn kinase,  
5.42 µM for PLK2 and 27.3 µM for SRC kinase; the concentration of α-SYN was 115 µM. After 
phosphorylation and prior to the aggregation assay pre-existing aggregates were removed by 
centrifugation at 8500 g for 30 min. Since ATP itself had an effect on the aggregation of α-SYN  
(see Supplementary Figure S3), it was removed by loading each sample on a PD-10 column.  
Elution was done in 100 µL fractions with 20 mM Tris pH 7.4. For the aggregation assays 30 µM of 
phosphorylated α-SYN in buffer B (20 mM Tris-HCl pH 7.4, 100 mM NaCl) was used unless 
otherwise stated. The control was subjected to the same conditions without addition of ATP and kinase. 
Protein concentrations were re-determined after the PD-10 buffer exchange step prior to further testing. 
3.9. Mass Spectrometry 
Phosphorylated α-SYN (50 µg) was subjected to a TCA-acetone precipitation and digested for 3 h 
at 50 °C with 12 µg of thermolysin in the presence of 200 mM ammonium acetate and 20 mM CaCl2. 
For more information about the actual procedure see Supporting Information. 
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3.10. Western Blot Analysis 
After SDS-PAGE, proteins were blotted on a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, 
USA), which was rehydrated in methanol (2 s) and PBS (2 × 5 min) before use. After blotting (30 V, 1 h), 
the membrane was blocked in PBS-0.1% Triton (PBST) with 5% milk (Régilait skim milk,  
Saint-Martin-Belle-Roche, France) to avoid unspecific binding of the antibodies used. This was 
followed by incubation with the monoclonal mouse anti-α-SYN primary antibody (Zymed, San Francisco, 
CA, USA, 1:500 dilution in PBST-5% milk, 1 h), by a wash step (4 × 10 min, PBST), a secondary 
antibody incubation (horse radish peroxidase (HRP)-labeled goat anti-mouse polyclonal antibody 
(DAKO, Glostrup, Denmark), 1:10,000 dilution in PBST, 30 min) and a final wash step (4 × 10 min, 
PBST). Protein bands were visualized with the ECL detection kit (GE healthcare) using a LAS-3000 
Mini imager (Fujifilm, Tokyo, Japan). Blots were analysed by the AIDA image analyzer software. 
3.11. Transmission Electron Microscopy (TEM) 
For the TEM measurements, 300-mesh carbon and formvar coated copper grids were used. After 
adsorption (for 2 min) of the α-SYN samples onto the grids, they were negatively stained with 1% 
uranyl acetate for 30 s. The samples were examined with a Zeiss EM 10C electron microscope JEOL 
JEM2100 LaB6 (Zeiss, Zaventem, Belgium) operating at 200 KeV. A magnification of 5000 was used 
to get an overview image. For more detailed pictures of the fibrils a magnification of 20,000 was used. 
3.12. Peptidyl Prolyl Cis-Trans Isomerase Activity of FKBP12 
For more information about the activity assay see Supporting Information. 
4. Conclusions  
In normal physiological conditions only about 4% of α-SYN is phosphorylated on S129 [14,17].  
In this study we show that phosphorylation on S129 is not necessary for, or does not appear to 
promote, the aggregation of α-SYN, since its fibrillization kinetics are comparable to that of the  
WT protein. Previous work however shows that an increase in pS129-α-SYN is observed under  
certain conditions such as proteasomal inhibition, oxidative stress, mitochondrial complex 1 
dysfunction and an increase in iron levels, which are all implicated in PD [17,55,56]. This elevated 
pS129 could be caused by upregulated kinase activity, as has been shown for CKII [22,56],  
by decreased phosphatase activity or a decrease in degradation of phosphorylated α-SYN. For these 
reasons, the reversal of upregulated pS129 by pharmacological inhibition of kinases phosphorylating 
S129 has been proposed as a therapeutic venue for PD [57]. Given our data that phosphorylation 
mutants behave so differently biochemically from phosphorylated α-SYN, it may be interesting to 
develop cellular and in vivo disease models based on the modulation of pS129 levels via manipulation 
of the kinases and phosphatases regulating that phospho-site. Our study also indicates that future 
research is warranted to study the influence of FKBPs on cellular aggregation of phosphorylated  
α-SYN as well as the study of other effectors of α-SYN aggregation and their effect on the aggregation 
kinetics of the phosphorylated protein. 
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Supporting Information 
Figure S1. General aggregation properties of WT α-SYN and phosphorylation mutants. 
The aggregation kinetics were monitored by turbidity measurements at 350 nm under 
continuous shaking (270 rpm) at 37 °C. The concentration of α-SYN was 50 µM.  
(A) Representative measurement showing the same trends as observed in ThioT experiments, 
both tyrosine phosphorylation mutants aggregate slower (Y125F (white squares) and 
Y125E (gray squares)) while both serine phosphorylation mutants (S129A (white triangles), 
S129D (gray triangles) aggregate as fast as WT α-SYN (white circles); (B) Mean halftimes 
of at least three independent measurements (each done in triplicate) with SEM shown on 
each bar; and (C) Mean end phase amplitude. * indicates a statistical significant difference 
when compared to WT with a p-value < 0.05.  
 
Figure S2. Size distribution of (phosphorylated)-α-SYN before aggregation using FCS. 
Measure of diffusion coefficients of phosphorylated α-SYN compared to the non-phosphorylated 
control using FCS. pS129-α-SYN (dark yellow): phosphorylated α-SYN on S129 using 
PLK2, pY125-α-SYN (dark blue): phosphorylated α-SYN using Fyn kinase. In order to 
perform FCS, trace amounts of A140C-α-SYN, labeled with Alexa 488 nm was added, as 
described in the Materials and Methods section (A) Mean D of at least four independent 
measurements, SEM shown on each bar. No significant difference was seen between the 
mean D (86.4 +/− 4.95 to 92.3 +/− 3.8 µm2/s), corresponding to the monomeric form of the 
protein; and (B) Mean hydrodynamic radius calculated from D assuming a spherical 
particle. No significant difference was observed between p129-, pY125- and WT ctl-SYN. 
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Figure S3. Effect of ATP on the aggregation kinetics of a-SYN. The kinetics of the 
fibrillization process of α-SYN WT in the presence and absence of ATP followed by a 
Thioflavin T assay under continuous shaking (270 rpm) at 37 °C. A concentration of  
50 µM α-SYN was used in each experiment. (A) Representative figure showing an 
inhibitory effect of ATP in α-syn fibrillization. The halftimes of fibrillization are expressed 
as percentages of WT, which was set to 100%; (B) Mean values of the halftimes;  
(C) Mean end phase fluorescence intensities; (B) and (C) are calculated from five 
independent measurements (n = 5) each done in quadruplicate, with the standard error of mean 
(SEM) shown on each bar; and (D) Laser scanning microscopy images at the slide surface 
during the course of the fluorescence correlation spectroscopy (FCS) experiments. Scale bar, 
50 µm (valid for all panels). In these experiments, alpha-synuclein is mixed with fluorescently 
labelled alpha-synuclein as described in materials and methods. Shown here is that the 
presence of ATP in the analysis mixture leads to rapid deposition of large amorphous 
aggregates, in contrast to the deposition of aggregates of fibrillar form in normal samples. 
These experiments illustrate that the presence of ATP in the in vitro aggregation assays 
cause a time dependent non-fibrillar aggregation of alpha-synuclein, explaining the low 
end phase fluorescence intensity in the ThioT assay. For this reason, ATP is removed from 
all aggregation assays of this study, as described in Materials and Methods.  
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Figure S4. ESI-MS/MS spectra of phosphopeptides of thermolysin digested α-synuclein 
after (A) SNK phosphorylation and (B) FYN phosphorylation.  
 
 
(A) 
 
(B) 
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Fluorescent Labeling 
For fluorescent labeling of α-SYN the A140C mutant is used, which was purified as described 
above. The protein (200 μM) was labeled with a 20-fold molar excess of Alexa 488–C5-maleimide 
(Invitrogen, Carlsbad, CA, USA) in 20 mM Tris buffer pH 7.4. The protein was incubated for 2 h at 
room temperature while stirring (100 rpm). Labeled protein was separated from free dye by gel 
chromatography using a double PD-10 column (GE Healthcare). C-terminal Alexa labeled α-SYN was 
used for FCS measurements. The efficiency of labeling is approximately 42% and was calculated using 
the extinction coefficients ε(280 nm (α-SYN)) = 5800, ε(280 nm (Alexa Fluor 488 nm)) = 920 and ε(493 nm (Alexa Fluor 488 nm)) = 
72,000 cm−1 M−1 through use of the following equation: 
 =  (S1)
The aggregation rate of A140C is comparable to WT as measured by turbidity and thioflavin T 
(ThioT) fluorescence [58]. 
Fluorescence Correlation Spectroscopy (FCS) 
A small fraction (<10%) of free dye is present in all measured samples, probably due to the 
presence of non-specifically bound dye molecules that are not fully removed by the gel chromatography 
after labeling, and are released upon dilution to nanomolar concentrations. For each time point,  
16 measurements were done, each with a time lapse of 10 s, and every curve was fitted using the 
following two component model (Equations (S2–S4)): 
 (S2)
 (S3)
 (S4)
GT is the part of the autocorrelation curve at a fast timescale, representing the photodynamics; GD is 
the concentration-dependent part representing diffusion;  is the correlation time;  and  are the 
amplitude and the relaxation time of the photodynamic process; N is the average number of particles in 
the confocal volume; (F1) and (1 − F1) are respectively the diffusion time (fraction) of free  
Alexa dye and dye bound to α-SYN;  and are the radial and axial radii of the confocal volume, 
which are determined in the calibration with Alexa 488 (D = 435 μm2 s−1) [59] and are fixed 
throughout the measurements. 
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Mass Spectrometry 
Identification of phosphopeptides in thermolysin digested α-synuclein after SNK and FYN 
phosphorylation was executed both with MALDI-TOF/TOF and LC-ESI-MS/MS. In brief, one tenth 
of the sample of phosphorylated α-synuclein (note: the same sample which is used in the in vitro 
aggregation tests) was subjected to phospho-enrichment on PhosTrap beads (Perkin Elmer, Waltham, 
MA, USA) according to manufacturer’s instructions. The PhosTrap eluate was divided in two for 
MALDI and ESI analysis, respectively. These eluates were used to detect the nature of the 
phosphorylated species in the thermolysin digest. The identity of the peptides was confirmed by 
MS/MS in both ionization modes. In the next step, the non-phosphorylated counterparts of these 
phosphopeptides were quantified in non-phosphoenriched samples. MALDI analysis was executed on a 
4800 MALDI TOF/TOF instrument (ABSCIEX, Framingham, MA, USA) in the reflectron mode. ESI 
analysis was executed on a 4000 QTRAP instrument (ABSCIEX) coupled to a Dionex Ultimate capillary 
liquid chromatography system. Peptides were separated on a PepMap C18 column developed with a  
30 min linear gradient (0.1% formic acid-6% acetonitrile-water to 0.1% formic acid–40%  
acetonitrile–water). MRM (multiple reaction monitoring)-induced product (+) ion scanning was used 
to identify and quantify (MultiQuant 1.1, ABSCIEX, Framingham, MA, USA) peptides. 
Calculation of percentage phosphate incorporation, was executed based on the quantification of 
non-phosphorylated equivalents of the phosphopeptides in non-phosphorylated synuclein, SNK 
phosphorylated synuclein and FYN phosphorylated synuclein, adapted from a method described  
by Olsen and colleagues [60] (Olsen et al. 2010), which was originally developed to calculate  
peptide phosphorylation stoechimetries if MS data of phosphopeptides (P), of the corresponding  
non-phosphopeptides (NP), and of relative protein abundance (z) are available in two conditions  
(H and L) of a SILAC experiment. 
P H + NP H = z (P L + NP L) (S5)
P H/P L = x (S6)
NP H/NP L = y (S7)
A a result: P L/NP L = (z − y)/(x − z) (S8)
In the adapted calculation employed here, the H and L conditions are replaced with CTRL and SNK 
(or FYN), respectively. In this way, the following equations are obtained: 
NP CTRL/NP SNK = y (S9)
P SNK/NP SNK = (z − y)/(0 − z) (S10)
x = 0 because there is no phosphorylation in CTRL condition;  
y is known from relative abundancies of non-phosphopeptides in MS;  
z is known from initial protein concentration measurements. 
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Peptidyl prolyl Cis-Trans Isomerase Activity of FKBP12 
The isomerase activity of FKBP12 was determined following the protocol of Kullertz et al [61]  
(Kullertz et al. 1998). Four microliters of FKBP12 or 4 µL of buffer (35 mM Hepes pH = 7.4) was 
added to 40 µL chymotrypsin (1 g/L in 35 mM Hepes pH = 7.4). After addition of the substrate  
(400 µL of succinimidyl-Phe-Pro-Phe-4-nitroanilide (Bachem, Torrance, CA, USA)) the reaction was 
monitored at 390 nm. The obtained curves were fitted to the equation below (Equation (S11)) to obtain 
the first order rate constant of the reaction. 
Y =  (S11)
The specific enzymatic activity was determined using Equation (S12): 
 (S12)
 = concentration of hFKBP12 used, k0 = the observed rate constant of the uncatalyzed reaction 
and kobs = the observed rate constant in the presence of FKBP12. KM is the Michaelis-Menten constant 
and kcat = the catalytic rate constant. 
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